Intuitive Surgical Stock Has Seen Growth of 34% Year-to-Date
Intuitive Surgical’s stock price rose from $364.94 at the close of market on December 29, 2017, to $489.57 on November 23, 2018.
How TransEnterix Has Been Performing in November
In this series, we’ll explore TransEnterix’s financials, analyst recommendations, and valuation metrics.
How Wall Street Analysts View TransEnterix
Of the five analysts tracking TransEnterix in July, two of them have recommended a “strong buy,” and one has recommended a “buy.”
Analyzing the SurgiBot System Assets Sale by TransEnterix
TransEnterix’s enterprise value stands at ~$686.7 million, and its enterprise-value-to-revenue ratio is ~69.1.
Intuitive Surgical Plans to Expand in Europe and Asia
Although Intuitive Surgical leads the surgical robotics market, there are competitive threats from other major players in the market.
What to Expect from Intuitive Surgical’s 2Q17 Earnings
Analysts estimate that Intuitive Surgical will post 2Q17 EPS (earnings per share) of ~$4.76. In 1Q17, Intuitive Surgical exceeded analysts’ diluted EPS estimate of $4.67.
2Q16 Revenue Estimates for Intuitive Surgical
On July 19, 2016, Intuitive Surgical (ISRG) will announce its 2Q16 earnings. Wall Street has estimated the company’s 2Q16 revenues will come in at ~$640 million.
Company Overview: An Introduction to Intuitive Surgical
Intuitive Surgical is a pioneer of minimally invasive robotic surgery. It develops and manufactures da Vinci surgical systems and related instruments.
Analyzing Intuitive Surgical’s R&D Strategy and Innovations
Intuitive Surgical is continuously enhancing its product offerings, enabling more efficient procedures through internal research and development (or R&D).